Request Demo

Last update 28 Sep 2026

Dronabinol

Last update 28 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(-)-delta9-trans-Tetrahydrocannabinol, 1-trans-delta-9-Tetrahydrocannabinol, 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo(b,d)pyran-1-ol

+ [40]

Target

Action

agonists

Mechanism

CB agonists(Cannabinoid receptor agonists)

Therapeutic Areas

Other DiseasesNervous System DiseasesDigestive System Disorders+ [5]

Active Indication

AnorexiaNauseaVomiting+ [13]

Inactive Indication

Depressive DisorderMultiple SclerosisTourette Syndrome

Originator Organization

AbbVie, Inc.

Active Organization

Avicanna, Inc.

Tetra Bio-Pharma, Inc.

RespireRx Pharmaceuticals, Inc.

+ [8]

Inactive Organization

Unimed Pharmaceutical, Inc.

Solvay SA

SciSparc Ltd.

+ [1]

License Organization

IntelGenx Corp.

Alkem Laboratories Ltd.

DanCann Pharma A/S

+ [6]

Drug Highest PhaseApproved

First Approval Date

United States (31 May 1985),

AnorexiaNauseaVomiting

RegulationBreakthrough Therapy (United States), Orphan Drug (United States)

Structure/Sequence

Molecular FormulaC21H30O2

InChIKeyCYQFCXCEBYINGO-IAGOWNOFSA-N

CAS Registry1972-08-3

374

Clinical Trials associated with Dronabinol

NCT05432284

/ Not yet recruitingPhase 1IIT

Behavioral Pharmacology of THC and Beta-Myrcene

This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized b-myrcene and THC administered via inhalation.

Start Date01 Jul 2027

Sponsor / Collaborator

The Johns Hopkins University

[+1]

NCT07224698

/ Not yet recruitingPhase 2IIT

Phase 2 Multicenter Randomized Placebo-controlled, Double-blind, Parallel Study to Assess the Safety and Efficacy of Inhaled Cannabis in Veterans for Treatment of Posttraumatic Stress Disorder (PTSD)

The rationale for the use of inhalational cannabis to potentially treat PTSD symptoms is based on the many reports of cannabis attenuating PTSD symptom expression among individuals with PTSD, including veterans. Study MJP2 is intended to build off MJP-1 through use of a larger sample size, a parallel study design, and subjective bias mitigation methods to re-examine the use of inhaled high THC-containing cannabis versus placebo for management of PTSD symptoms in a U.S. Veteran sample. Together these studies are intended to provide valuable insights on the already widespread use of cannabis in individuals with PTSD, for which there is currently a lack of controlled evidence available reflective of this real-world use.

Start Date01 Feb 2027

Sponsor / Collaborator

Multidisciplinary Association for Psychedelic Studies

ACTRN12620000847910

/ Not yet recruitingPhase 1/2

Safety and Effect of Medical Cannabis on Relapse among 20 Patients with Methamphetamine Use Disorder: A Proof-of-Concept Trial

Start Date01 Dec 2026

Sponsor / Collaborator

University of Edith Cowan

100 Clinical Results associated with Dronabinol

100 Translational Medicine associated with Dronabinol

100 Patents (Medical) associated with Dronabinol

11,712

Literatures (Medical) associated with Dronabinol

31 Dec 2026·PLATELETS

Pilot study on cannabis-induced alterations in platelet function: implications for transfusion medicine

Article

Author: Loubaki, Lionel ; Cognasse, Fabrice ; Hamzeh-Cognasse, Hind ; Laflamme, Geneviève

Platelet transfusions are essential in the management of thrombocytopenia, bleeding disorders, and hematologic malignancies. With cannabis use rising worldwide, its impact on donor platelet quality and transfusion efficacy remains poorly understood. This study investigated the effects of cannabis joint extracts (CJE) on platelet activation, pro-coagulant phenotype, mitochondrial function, and cytokine/chemokine release, with implications for transfusion safety. Human platelets were exposed in vitro to increasing concentrations of two CJE with distinct cannabinoid profiles: Orchid (O-CJE, THC 10.4%, CBD 14.7%) and QCGold (G-CJE, THC 25.5%, CBD 0.04%). Platelet activation (CD62P, Annexin V), mitochondrial depolarization, ATP levels, aggregation responses, and cytokine secretion (CCL3, PF4) were assessed. RBC lysate experiments were performed to assess the role of hemolysis. The involvement of CB1 and CB2 receptors was tested using specific antagonists, and activation of p38 MAPK and NF-κB pathways was evaluated. Functional effects of platelet supernatants were examined on EA.hy926 endothelial cells. CJE exposure induced dose-dependent platelet activation, characterized by increased CD62P expression, Annexin V binding, mitochondrial depolarization, and ATP depletion, consistent with metabolic stress. Platelet aggregation in response to ADP, collagen, and arachidonic acid was impaired, suggesting a pre-activated or refractory phenotype. RBC lysate did not reproduce the observed effects, indicating hemolysis is unlikely to be the underlying mechanism. CBR1 and CBR2 antagonists did not attenuate platelet activation, while signaling analysis revealed activation of p38 MAPK and NF-κB pathways. Exploratory proteomics indicated modulation of proteins involved in angiogenesis, cytoskeletal organization, and stress responses. Elevated plasma levels of CCL3 and PF4 and endothelial activation (IL-6 secretion, CD54, CD62P, CD62E expression) further suggested a pro-inflammatory environment. Cannabis exposure can alter platelet phenotype and signaling under in vitro conditions, potentially affecting platelet function and interactions with the vascular endothelium. However, these findings require confirmation in vivo to determine their clinical relevance. Future studies should aim to establish exposure thresholds and clarify whether cannabis use has implications for transfusion safety, given potential risks of reduced efficacy or increased thrombotic complications in recipients.

01 Dec 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Application of liquid chromatography with tandem mass spectrometry detection for the determination of twelve cannabinoids in a feasibility study to produce a pharmacologically active ingredient from seized Cannabis sativa L. (marijuana)

Article

Author: de Cassia Mariotti, Kristiane ; de Oliveira Camargo, Flavio Anastacio ; Pereira, Danilo ; Ortiz, Rafael Scorsatto

The increasing demand for Cannabis-derived medicinal products in Brazil, coupled with the implementation of RDC 1013/2026 (ANVISA), necessitates robust analytical frameworks for pharmacological and forensic purposes. This study is part of the "Paracelsus Project," a feasibility study evaluating the production of plant-based active pharmaceutical ingredients (API) from seized Cannabis sativa L. (marijuana), aiming to repurpose material that is currently incinerated. Preliminary data suggests this seized material contained a total of roughly 25 tons of CBD. A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the simultaneous determination of twelve phytocannabinoids (CBD, D9-THC, D8-THC, CBC, CBL, CBN, CBG, THCV, CBDV, CBDVA, CBGA, and THCA). The methodology utilized a triple quadrupole (QQQ) analyzer in positive ionization mode, designed to overcome the challenges of complex plant matrices and chemical isomers. The method achieved successful baseline separation of critical pairs, such as CBD/CBG and D9-THC/D8-THC, in under eight minutes. This analytical workflow was successfully applied to monitor cannabinoid concentrations during the extraction and purification processes from seized marijuana by Brazilian Federal Police. The validated LC-MS/MS method provides the necessary sensitivity and specificity for both quality control in API production and forensic standardization. By establishing a technical foundation for characterizing medicinal extracts and ensuring compliance with the 0.3% THC statutory threshold, this research supports public health safety and the potential for a sustainable pharmaceutical supply chain from seized materials in Brazil.

01 Nov 2026·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

An improved method for quantification of cannabidiol, Δ9-tetrahydrocannabinol, and their metabolites in human plasma and urine

Article

Author: Hurd, Yasmin L ; Laprairie, Robert B ; Kudrich, Christopher ; Bachi, Keren ; van Oort, Jasper ; Zagzoog, Ayat ; Alcorn, Jane ; Ha, Nini ; Michel, Deborah

Cannabidiol (CBD), the second most prevalent phytocannabinoid in Cannabis sativa, potentially offers numerous therapeutic benefits without psychoactive effects. Research into CBD's therapeutic applications must be supported by an understanding of the time course of CBD concentrations in the body and how these concentrations relate to CBD's safety and efficacy. This study aimed to develop a simplified protocol for quantifying CBD, Δ⁹-Tetrahydrocannabinol (THC) and its metabolites in human plasma and urine, eliminating complex and time-consuming sample preparation, especially for urine samples, while maintaining accuracy comparable to traditional methods. This protocol was used to assess the influence of an oral capsule of CBD (BSPG CBD BRAINS Bioceutical laboratories) on the pharmacokinetics of CBD and its metabolites in plasma and urine relative to an FDA approved CBD formulation (Epidiolex®). The method development focused on optimizing mass spectrometry (MS) conditions with an ultra-high performance liquid chromatography (UHPLC) C18 column. Plasma and urine were collected at fourteen and eight time points, respectively, across 24 h and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS) to quantify CBD and its metabolites. Additionally, (THC) and its metabolites were examined, with no detectable levels found in either plasma or urine. This newly developed analytical method successfully quantified CBD and its metabolites in both plasma and urine, contributing valuable data to the understanding of CBD pharmacokinetics in different oral products. This study's findings have important implications for optimizing CBD administration and assessing therapeutic outcomes.

644

News (Medical) associated with Dronabinol

25 Sep 2026

·www.prnewswire.com

New Menopause Guide Explores How Women Are Using CBD, THC and CBN for Sleep, Mood and Everyday Wellness

Rare Cannabinoid Company's new educational guide examines the endocannabinoid system, current menopause research and the distinct roles of CBD, THC, CBN, CBG, CBC, THCV and CBDV during midlife. HONOLULU, Sept. 25, 2026 /PRNewswire/ -- As more women explore cannabis and hemp-derived cannabinoids during perimenopause and menopause, Rare Cannabinoid Company has published a comprehensive new educational guide examining what is known, what remains uncertain and how different cannabinoids may fit into a personalized midlife wellness routine. The new resource, " CBD for Menopause: A Guide to Cannabis, THC, CBN and Hemp ," explores growing interest in CBD for menopause, menopause gummies and cannabinoids for concerns involving sleep, mood, focus, appetite, energy and everyday physical comfort. Continue Reading Rare Cannabinoid Company’s new menopause guide explores how CBD, THC, CBN and other hemp-derived cannabinoids may support sleep, mood and everyday wellness during midlife. Menopause is a natural life transition, but fluctuating hormone levels during perimenopause can affect many aspects of daily wellbeing at once. Sleep disruption, mood changes, hot flashes, difficulty concentrating and changes in energy, appetite and physical comfort are among the experiences frequently reported during this stage of life. At the same time, women are increasingly seeking information about cannabis, CBD and lesser-known hemp cannabinoids. Yet much of the information available online either treats every cannabinoid as interchangeable or presents cannabinoids as a cure-all despite limited clinical research. Rare Cannabinoid Company developed its new guide to provide a more balanced and practical resource. "Women deserve clear information that acknowledges both the possibilities and the limitations of cannabinoids during menopause," said a spokesperson for Rare Cannabinoid Company. "CBD, THC, CBN, CBG, CBC, THCV and CBDV are distinct compounds with different properties. Our goal was to explain those differences, examine the emerging research and help women ask better questions when considering cannabinoids as part of their wellness routines." Why Are Women Exploring Cannabis and CBD During Menopause? The guide examines the relationship between menopause and the body's endocannabinoid system, a widespread signaling network involved in processes including sleep, mood, appetite, stress response, and physical comfort. Researchers have identified biological connections among estrogen signaling, endocannabinoid levels and cannabinoid-receptor activity. However, exactly how these relationships change throughout perimenopause, menopause and postmenopause is not yet fully understood. A published survey of medical cannabis use during perimenopause and postmenopause found that participants most commonly reported using cannabis for sleep and mood concerns. Many perceived cannabis as helpful, although the researchers emphasized the need for controlled clinical trials to determine which cannabinoids, formulations and amounts may be effective. Rare Cannabinoid Company's guide places that developing research in context without presenting cannabinoids as a replacement for hormones, medical care or proven menopause treatments. CBD, THC and CBN Are Not Interchangeable One of the guide's central messages is that there is no single "menopause cannabinoid." The resource explains why women may encounter very different cannabinoid ingredients when researching CBD for menopause or shopping for menopause gummies: CBD (cannabidiol) is non-intoxicating and commonly used to support calm, balance and everyday physical comfort. CBN (cannabinol) is primarily associated with nighttime relaxation and rest-focused routines and is commonly found in CBN gummies for sleep. THC (tetrahydrocannabinol) produces a more noticeable experience and is often used for deeper relaxation and soreness relief, but individual sensitivity and local laws must be considered. CBG (cannabigerol) gummies, oils and topical creams, lotions and gels are commonly selected for physical relief from discomfort, sore joints, and post-activity recovery. CBC (cannabichromene) is an emerging cannabinoid often associated with mood-oriented formulas, such as Mood Gummies, Mood Oils, and Mood Mints. THCV (tetrahydrocannabivarin) sounds similar to THC but has very different effects. THCV is generally used during the day for energy, focus and appetite-conscious routines, although it is not a proven menopause weight-loss treatment. CBDV (cannabidivarin) is a very rare, non-intoxicating cannabinoid that is often taken by those seeking greater social ease and less irritability. The guide also compares cannabinoid gummies, oils and topical products; explains the differences between products with and without THC; and discusses why serving size, timing and product testing matter. A More Thoughtful Approach to Menopause Gummies and Hemp Products The expanding market for CBD and menopause products can make it difficult for consumers to determine what they are actually buying. Products marketed broadly as "menopause gummies" may contain very different ingredients, potencies and cannabinoid combinations. Rare Cannabinoid Company encourages consumers to compare products according to the milligrams of each cannabinoid per serving, rather than relying on the total milligrams displayed on the package. The company also recommends looking for current independent laboratory reports verifying cannabinoid potency and screening for contaminants. The guide advocates a goal-based approach: identify the area in which support is most desired, select the cannabinoid that best corresponds with that goal and begin with a modest serving rather than introducing several new products simultaneously. It also encourages women to speak with a qualified healthcare professional before using cannabinoids if they take prescription medications, have a health condition, are considering hormone therapy or experience new or concerning symptoms. Cannabis and Menopause Research Is Still Developing Although real-world interest in CBD and cannabinoids during menopause is growing, clinical evidence remains limited. The guide distinguishes between established knowledge, early research and consumer-reported experiences while identifying questions that still require study. "Menopause is not one symptom, and women do not all experience it in the same way," the spokesperson said. "Cannabinoid education should reflect that complexity. There is no universal product or serving that will be right for everyone." About Rare Cannabinoid Company Rare Cannabinoid Company is a Hawaii-based American wellness company specializing in CBD, THC and rare hemp-derived cannabinoids, including CBN, CBG, CBC, THCV and CBDV. Since 2017, the company has developed targeted cannabinoid oils, gummies, mints and topical products designed for distinct wellness goals. Products are manufactured in cGMP-certified facilities and independently tested for purity and potency. Learn more at: SOURCE Rare Cannabinoid Company 21% more press release views with Request a Demo

25 Sep 2026

·www.sciencedaily.com

Don’t toss cannabis leaves: They may contain rare compounds with medical potential

Scientists discovered rare flavoalkaloids in Cannabis leaves for the first time, along with dozens of other phenolic compounds that had never been reported in the plant. The findings suggest that Cannabis leaves, often discarded as waste, may contain a surprisingly rich source of potentially useful chemicals.Scientists studying the chemistry of Cannabis leaves have uncovered something that had never been documented in the plant before: evidence of a rare group of natural compounds known as flavoalkaloids. Analytical chemists at Stellenbosch University (SU) made the discovery while examining the complex mixture of chemicals found in commercially grown Cannabis from South Africa. Their findings suggest that the leaves, which can be treated as low value plant material or waste, may contain a much richer collection of potentially useful compounds than previously recognized. Rare Compounds Hidden in Cannabis Leaves Flavoalkaloids belong to a broader family of plant chemicals known as phenolic compounds. Phenolics are produced naturally by plants and include substances involved in pigmentation, defense, and protection from environmental stress. One major subgroup, flavonoids, is especially well known. These compounds have drawn considerable interest from pharmaceutical researchers because many are associated with antioxidant, anti-inflammatory, and anti-carcinogenic properties. Flavoalkaloids, however, are much less common in nature. In the new analysis, the researchers detected 79 phenolic compounds across three strains of Cannabis grown commercially in South Africa. Of those, 25 had never previously been reported in Cannabis. Sixteen of the compounds were tentatively identified as flavoalkaloids, providing the first evidence that this rare class of chemicals occurs in Cannabis leaves. Even more strikingly, most of the flavoalkaloids appeared primarily in just one of the three strains. The findings were published in the Journal of Chromatography A. Cannabis Contains Hundreds of Different Metabolites Dr. Magriet Muller, an analytical chemist in the LC-MS laboratory of the Central Analytical Facility (CAF) at Stellenbosch University and first author on the paper, says studying plant phenolics can be especially difficult. These compounds are often present at very low concentrations, and their chemical structures can vary enormously. That makes it challenging to separate, identify, and distinguish one compound from another within an already complex plant sample. "Most plants contain highly complex mixtures of phenolic compounds, and while flavonoids occur widely in the plant kingdom, the flavoalkaloids are very rare in nature," she explains. The chemical complexity of Cannabis made the results particularly surprising. The plant is already known to contain hundreds of metabolites, a broad term for small molecules produced through biological and chemical processes inside living organisms. "We know that Cannabis is extremely complex - it contains more than 750 metabolites - but we did not expect such high variation in phenolic profiles between only three strains, nor to detect so many compounds for the first time in the species. Especially the first evidence of flavoalkaloids in Cannabis was very exciting." Advanced Chemistry Reveals What Earlier Tests Could Miss The discovery grew out of analytical techniques Muller developed during her postgraduate studies in SU's Department of Chemistry and Polymer Science. Her methods combine comprehensive two-dimensional liquid chromatography with high-resolution mass spectrometry. Liquid chromatography separates the many different chemicals in a mixture so that researchers can study them individually. In two-dimensional liquid chromatography, compounds are separated in two different ways, giving scientists much greater resolving power when working with samples containing many closely related chemicals. High-resolution mass spectrometry then helps identify those compounds by measuring their molecular masses with extremely high precision. Together, the techniques allowed the researchers to examine the phenolic chemistry of Cannabis in far greater detail. "We were looking for a new application for the methods that I developed, after successfully testing them on rooibos tea, grapes and wine. I then decided to apply the methods to Cannabis because I knew it was a complex sample, and that Cannabis phenolics have not been well characterized," she explains. Separating Rare Compounds From Abundant Ones According to Prof. André de Villiers, Muller's study leader and main author on the paper, the separation achieved using the technique was key to spotting the rare compounds. He said he was blown away by the chromatographic results Muller obtained. "The excellent performance of two-dimensional liquid chromatography allowed separation of the flavoalkaloids from the much more abundant flavonoids, which is why we were able to detect these rare compounds for the first time in Cannabis." De Villiers leads the analytical chemistry research group in SU's Department of Chemistry and Polymer Science. The result highlights an important challenge in plant chemistry. Rare compounds can easily be obscured by other chemicals that occur in much larger quantities. Better separation methods can therefore reveal substances that were present all along but were difficult to distinguish using less powerful techniques. Looking Beyond THC and Other Cannabinoids Much of the scientific attention surrounding Cannabis has historically focused on cannabinoids, the group of compounds that includes substances responsible for many of the plant's well known pharmacological and mood effects. De Villiers argues that the new findings show how much remains to be learned about the plant's non-cannabinoid chemistry. The leaves in particular may deserve closer scrutiny. Plant material that is currently regarded as waste could contain phenolic compounds with properties that make them interesting for future biomedical research. "Our analysis again highlights the medicinal potential of Cannabis plant material, currently regarded as waste. Cannabis exhibits a rich and unique non-cannabinoid phenolic profile, which could be relevant from a biomedical research perspective," he concludes.

23 Sep 2026

·www.globenewswire.com

SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations

The U.S. patent applications cover proprietary combinations of NeuroThera’s PEA technology with LSD, ketamine and ibogaine for potential therapeutic applications, including mental health disorders, such as depression and PTSD as well as substance use disorders TEL AVIV, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND). As part of the collaboration, three U.S. patent applications have been published covering novel combinations of lysergic acid diethylamide (“LSD”), ketamine and ibogaine with N-acylethanolamines, including palmitoylethanolamide (“PEA”), NeuroThera’s proprietary technology. The applications cover potential therapeutic uses across a range of indications, including mental health disorders such as depression and post-traumatic stress disorder, as well as pain and substance use disorders. These U.S. patent applications build on previously announced intellectual property generated through the collaboration, including a U.S. patent application covering the combination of MDMA and N-acylethanolamines for potential treatment of PTSD, anxiety and eating disorders. The continued maturation of the patent portfolio reflects the broader potential applications of NeuroThera’s PEA technology when combined with psychoactive compounds such as psychedelic compounds. NeuroThera believes that these combinations may support the development of novel therapeutic approaches across multiple neuropsychiatric and substance use disorder indications. NeuroThera and Clearmind continue to advance their collaboration, aimed at bringing safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions. The companies remain focused on combining PEA with psychedelic‑derived compounds, while enhancing the intellectual property portfolio supporting these innovative therapeutic programs About SciSparc Ltd. (Nasdaq: SPRC): The Company, through its subsidiary NeuroThera, engages in clinical-stage pharmaceutical developments. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company, together with its majority-owned subsidiary NeuroThera, is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette syndrome, for the treatment of Alzheimer's disease and agitation; and SCI- 210 for the treatment of autism spectrum disorder and status epilepticus. The Company, through NeuroThera, also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on the Amazon.com Marketplace. About NeuroThera Labs Inc. NeuroThera is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc uses forward-looking statements when it discusses the potential therapeutic uses of NeuroThera’s product candidates across a range of indications, the broader potential applications of NeuroThera’s PEA technology, the potential of NeuroThera and Clearmind to bring safer and more effective treatments to market for some of the most common and rapidly growing mental‑health conditions, and continued enhancement of the intellectual property portfolio supporting these innovative therapeutics. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in SciSparc’s Annual Report on Form 20-F, filed with the SEC on April 29, 2026, as amended, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@scisparc.comTel: +972-3-6167055

100 Deals associated with Dronabinol

External Link

KEGG	Wiki	ATC	Drug Bank
D00306	Dronabinol	A04AD10	DB00470

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anorexia	United States	Alkem Laboratories Ltd.	31 May 1985
Nausea	United States	Alkem Laboratories Ltd.	31 May 1985
Vomiting	United States	Alkem Laboratories Ltd.	31 May 1985

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	NDA/BLA	Canada	Tetra Bio-Pharma, Inc.	01 May 2023
Lumbosacral Radiculopathy	Phase 3	United States	Vertanical GmbH	22 Sep 2026
Agitation in Dementia	Phase 3	Australia	Benuvia Therapeutics, Inc.	01 May 2026
Alzheimer Disease	Phase 3	Australia	Benuvia Therapeutics, Inc.	01 May 2026
Sleep Apnea, Obstructive	Phase 3	United States	RespireRx Pharmaceuticals, Inc.	01 Feb 2023
Low Back Pain	Phase 3	Germany	Vertanical GmbH	07 Jul 2021
Decrease in appetite	Phase 3	Europe	Solvay SA	15 Feb 2007
Diabetic peripheral neuropathic pain	Phase 3	United States	Vertanical GmbH	-
Osteoarthritis	Phase 3	United States	Vertanical GmbH	-
Osteoarthritis	Phase 3	Canada	Avicanna, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03106363 (CTgov)	Not Applicable	Psychomotor Disorders	49	alcohol+delta 9 tetrahydrocannabinol (Active Alcohol/Active Cannabis)	fmhlxqrwnh(zxxntaftxz) = veqskkrknx uiafmtsqit (brfrbeqgxj, fsradlrujo - xthytqtomr) View more	-	24 Jul 2026
				placebo alcohol+delta 9 tetrahydrocannabinol (Placebo Alcohol/Active Cannabis)	fmhlxqrwnh(zxxntaftxz) = tjdgxvfwvf uiafmtsqit (brfrbeqgxj, femctowapj - brqaxoporn) View more
NCT06471647 (ETS, CTgov)	Early Phase 1	Stress, Psychological \| Thrombocytopenia 1	36	Placebo (Placebo)	srwxgfkvsl(qvjtxkcsvk) = dlslorxqeq jrnfkffqpj (lemjmnsgwt, 6.6) View more	-	09 Jul 2026
				THC (5 mg Delta-9-tetrahydrocannabinol (THC))	srwxgfkvsl(qvjtxkcsvk) = twylkitymx jrnfkffqpj (lemjmnsgwt, 6.5) View more
NCT03661892 (Pubmed \| Oncologist)	Phase 2	Ostealgia	14	Dronabinol 10 mg	fnpjnevbwe(pgkdcpvgdb) = dizziness uxwckcfxvu (kwlsdmmwwb ) View more	Positive	08 Jul 2026
ASCO2026	Not Applicable	Neoplastic Processes	26	naproxen	xnftowbnec(hxpsuhkowh) = sbiqzwrxru lbdjpqcdcr (yptfcowvzy, 82.2 - 90.0)	Positive	29 May 2026
				indomethacin	xnftowbnec(hxpsuhkowh) = kltekivyav lbdjpqcdcr (yptfcowvzy, 70.5 - 87.5)
NCT02983773 (CTgov)	Phase 2	Marijuana Abuse	157	Placebo (Placebo)	sfabwgfrpx(pzpgrsvtzf) = tjfzwuwwry xapmbjbfrd (jhbbxtmawh, 1.01) View more	-	21 Apr 2026
				THC 7.2% (7.2% THC)	jmufbqtnjj(agcpquckau) = nzoapabrjv hxznhbcmjm (ssmfwmnmxy, 2.33) View more
NCT04734080 (CTgov)	Phase 4	-	114	Dronabinol 5mg Cap (Dronabinol)	zgpunjphjl(sscjqxtbml) = dzbolyldxv upyvvmsugb (ticntfvbyf, jenvlleatj - mbkmwlnzjn) View more	-	27 Mar 2026
				Placebo oral tablet (Placebo)	zgpunjphjl(sscjqxtbml) = rxnqizqznc upyvvmsugb (ticntfvbyf, sdmjidvafz - uqfcwwbvkn) View more
NCT04360044 (Pubmed \| Headache)	Phase 2	Migraine Disorders	92	6% Δ9-tetrahydrocannabinol (THC)	wzphmnlgwd(beaznjvnqw) = sgpdktsjbx ssmalkdstf (njejqbflgf ) View more	Positive	01 Feb 2026
				6% THC + 11% CBD	wzphmnlgwd(beaznjvnqw) = ctixzpdgyd ssmalkdstf (njejqbflgf ) View more
ASH2025	Phase 2	Chronic Pain \| Anemia, Sickle Cell	30	Dronabinol	vspmbvucxe(sipzasjyhr) = axjomwdomf zkvfohgcid (sayhdhpkjo ) View more	Positive	06 Dec 2025
				Placebo	vspmbvucxe(sipzasjyhr) = vsvpcpfjlm zkvfohgcid (sayhdhpkjo ) View more
NCT03978156 (Pubmed \| Pilot Feasibility Stud)	Phase 2	Anemia, Sickle Cell	6	Dronabinol	ykglfnxknr(ecmqlrpjuh) = vwfxyaptqf tkuuotgndv (phjjgeqcru ) View more	Positive	12 Nov 2025
NCT02792257 (THC-AD, Pubmed \| Am J Geriatr Psychiatry)	Phase 2	Agitation in Dementia	75	Dronabinol	owpmqqvdky(wjrtufrurb): Difference = -1.26, P-Value = 0.094 View more	Positive	01 Nov 2025
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis